Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability.
OBJECTIVE
To compare intraocular pressure (IOP) rise in normal individuals and primary open-angle glaucoma patients and the safety and efficacy of ibopamine eye drops in different concentrations as a provocative test for glaucoma.


METHODS
Glaucoma patients underwent (same eye) the ibopamine provocative test with two concentrations, 1% and 2%, in a random sequence at least 3 weeks apart, but not more than 3 months. The normal individuals were randomly submitted to one of the concentrations of ibopamine (1% and 2%). The test was considered positive if there was an IOP rise greater than 3 or 4 mmHg at 30 or 45 minutes to test which subset of the test has the best sensitivity (Se)/specificity (Sp).


RESULTS
There was no statistically significant difference in any of the IOP measurements, comparing 1% with 2% ibopamine. The IOP was significantly higher at 30 and 45 minutes with both concentrations (p < 0.001). The best sensitivity/specificity ratio was achieved with the cutoff point set as greater than 3 mmHg at 45 minutes with 2% ibopamine (area under the ROC curve: 0.864, Se: 84.6%; Sp:73.3%). All patients described a slight burning after ibopamine's instillation.


CONCLUSIONS
2% ibopamine is recommended as a provocative test for glaucoma. Because both concentrations have similar ability to rise IOP, 1% ibopamine may be used to treat ocular hypotony.
Magacho
Leopoldo
L
Sector de Glaucoma do Centro de Referência em Oftalmologia da Universidade Federal de Goiânia (GO), - Brasil. lmagacho@brturbo.com.br
Costa
Marcelus Layguel
ML
Dessimoni
André
A
de Avila
Marcos Pereira
MP
D000368:Aged; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018491:Dopamine Agonists / Q000008:administration & dosage; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009184:Mydriatics / Q000008:administration & dosage; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013997:Time Factors; D014787:Vision Tests
D018491:Dopamine Agonists; D009184:Mydriatics; D009883:Ophthalmic Solutions; C023487:ibopamine; D003846:Deoxyepinephrine